Видео ютуба по тегу Metastasis Inhibition

Bisphosphonates vs. RANK ligand inhibition in bone metastases
Bisphosphonates vs. RANK ligand inhibition in bone metastases
Metastatic gastric cancer: Indications and impact of stem-cell inhibition
Metastatic gastric cancer: Indications and impact of stem-cell inhibition
Metastasis inhibition
Metastasis inhibition
HR+ Breast Cancer: CDK4/6 Inhibitors & Sites of Metastasis
HR+ Breast Cancer: CDK4/6 Inhibitors & Sites of Metastasis
PARP inhibitors for metastatic breast cancer
PARP inhibitors for metastatic breast cancer
The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancer
The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancer
IDO Inhibitors in Metastatic Melanoma
IDO Inhibitors in Metastatic Melanoma
PI3K inhibitors for the treatment of brain metastases in HER2-negative breast cancer
PI3K inhibitors for the treatment of brain metastases in HER2-negative breast cancer
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Focal Adhesion Kinase Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteo
Focal Adhesion Kinase Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteo
Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Current Data and Clinical Use
Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Current Data and Clinical Use
CDK4/6 Inhibitors in Metastatic Disease
CDK4/6 Inhibitors in Metastatic Disease
Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer
Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer
HR+ Metastatic Breast Cancer: Upfront CDK4/6 Inhibition
HR+ Metastatic Breast Cancer: Upfront CDK4/6 Inhibition
First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer
First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer
The potential of PARP inhibitors for metastatic cancer
The potential of PARP inhibitors for metastatic cancer
Metastatic Breast Cancer: CDK4/6 Inhibitors
Metastatic Breast Cancer: CDK4/6 Inhibitors
CDK Inhibitors in Metastatic Hormone-Driven Breast Cancer
CDK Inhibitors in Metastatic Hormone-Driven Breast Cancer
BRAF/MEK Inhibitors in Metastatic Melanoma
BRAF/MEK Inhibitors in Metastatic Melanoma
Challenging results from mTOR inhibitors in metastatic clear cell renal cancer
Challenging results from mTOR inhibitors in metastatic clear cell renal cancer